Nicholas Warren

Science Policy Program Administrator, AACR's Office of Science Policy and Government Affairs

The AACR's Office of Science Policy and Government Affairs organizes a number of activities like briefing Congress on the latest breakthroughs, bringing AACR members DC to advocate for research funding, commenting on new regulations at executive agencies, and facilitating discussions about up and coming regulatory issues between academic, industry, and government scientists. My position involves helping many aspects of the office, but with a significant focus on cancer prevention policy, like tobacco and e-cigarettes, or HPV vaccines. It's a great opportunity to help the AACR stay up to date on emerging policy and help the AACR influence the policy making process. The broad scientific background and emphasis on human aspects of cancer treatment that PEMM gave me has really helped me separate the noise from the signal in terms of what is happening in DC. Whether I was at the bench in PEMM or my policy work now at AACR, the goal at the end of the day has always been to improve the lives of cancer patients.  


HB 7936


  • B.S. University of Wisconsin - Eau Claire
  • Ph.D. '19, Experimental and Molecular Medicine, Dartmouth College

Selected Publications

  • Warren N, Strom A, Nicolet B, Albin K, Albrecht J, Bausch B, Dobbe M, Dudek M, Firgens S, Fritsche C, Gunderson A, Heimann J, Her C, Hurt J, Konorev D, Lively M, Meacham S, Rodriguez V, Tadayon S, Trcka D, Yang Y, Bhattacharyya S, Hati S. Comparison of the intrinsic dynamics of aminoacyl-tRNA synthetases. The Protein Journal. 2014 March 4. 

  • Warren N, Eastman A. Inhibition of checkpoint kinase 1 following gemcitabine-mediated S phase arrest results in CDC7- and CDK2-dependent replication catastrophe. The Journal of Biological Chemistry 294, 1763-1778. 2018 December 20.

  • Warren N, Eastman A. Reply to Koh: Signaling dynamics of DNA damage response invoked by combination therapy are dose-dependent. The Journal of Biological Chemistry 294, 2192. 2019 February 8.

  • Warren N, Donahue K, Eastman A. Differential Sensitivity to CDK2 Inhibition Discriminates the Molecular Mechanisms of CHK1 Inhibitors as Monotherapy or in Combination with the Topoisomerase I Inhibitor SN38. ACS Pharmacol. Transl. Sci., DOI: 10.1021/acsptsci.9b00001. 2019 April 4.

Selected Works & Activities

  • Warren, N., Sheetz, P. (2017) We are Dartmouth too. The Dartmouth. Hanover, NH. Editor: Solomon, I.

  • Warren, N. (2017) Taxing Graduate Students. Valley News. West Lebanon, NH. Editor: Mackie, D.

  • Awards

    Albert J. Ryan Foundation Fellowship, 2016

    Best Poster Award, Molecular Therapeutics of Cancer Research Conference, University of Washington, Seattle WA, 2016

    Conference Travel Award, Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon NH, 2016

    ASPET Washington Policy Fellowship, 2019 

  • Laboratory

    Eastman Lab